Performance of Urinary Phenyl-γ-Valerolactones as Biomarkers of Dietary Flavan-3-ol Exposure.

Humans Glucuronides Flavonoids Tea / chemistry Sulfates Biomarkers Catechin / chemistry
apple biomarkers black tea cocoa flavan-3-ols flavonoids green tea phenyl-γ-valerolactones

Journal

The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243

Informations de publication

Date de publication:
08 2023
Historique:
received: 15 05 2023
revised: 20 06 2023
accepted: 26 06 2023
medline: 11 8 2023
pubmed: 3 7 2023
entrez: 2 7 2023
Statut: ppublish

Résumé

Phenyl-γ-valerolactones (PVLs) have been identified as biomarkers of dietary flavan-3-ol exposure, although their utility requires further characterization. We investigated the performance of a range of PVLs as biomarkers indicative of flavan-3-ol intake. We report the results of 2 companion studies: a 5-way randomized crossover trial (RCT) and an observational cross-sectional study. In the RCT (World Health Organization, Universal Trial Number: U1111-1236-7988), 16 healthy participants consumed flavan-3-ol-rich interventions (of apple, cocoa, black tea, green tea, or water [control]) for 1 d each. First morning void samples and 24-h urine samples were collected with diet standardized throughout. For each participant, 1 intervention period was extended (to 2 d) to monitor PVL kinetics after repeat exposure. In the cross-sectional study, 86 healthy participants collected 24-h urine samples, and concurrent weighed food diaries from which flavan-3-ol consumption was estimated using Phenol-Explorer. A panel of 10 urinary PVLs was quantified using liquid chromatography tandem mass spectrometry. In both studies, 2 urinary PVLs [5-(3'-hydroxyphenyl)-γ-valerolactone-4'-sulfate and putatively identified 5-(4'-hydroxyphenyl)-γ-valerolactone-3'-glucuronide] were the principal compounds excreted (>75%). In the RCT, the sum of these PVLs was significantly higher than the water (control) after each intervention; individually, there was a shift from sulfation toward glucuronidation as the total excretion of PVLs increased across the different interventions. In the extended RCT intervention period, no accumulation of these PVLs was observed after consecutive days of treatment, and after withdrawal of treatment on the third day, there was a return toward negligible PVL excretion. All results were consistent, whether compounds were measured in 24-h urine or first morning void samples. In the observational study, the sum of the principal PVLs correlated dose dependently (R Urinary 5-(3'-hydroxyphenyl)-γ-valerolactone-4'-sulfate and putatively identified 5-(4'-hydroxyphenyl)-γ-valerolactone-3'-glucuronide are recommended biomarkers for dietary flavan-3-ol exposure.

Sections du résumé

BACKGROUND
Phenyl-γ-valerolactones (PVLs) have been identified as biomarkers of dietary flavan-3-ol exposure, although their utility requires further characterization.
OBJECTIVES
We investigated the performance of a range of PVLs as biomarkers indicative of flavan-3-ol intake.
METHODS
We report the results of 2 companion studies: a 5-way randomized crossover trial (RCT) and an observational cross-sectional study. In the RCT (World Health Organization, Universal Trial Number: U1111-1236-7988), 16 healthy participants consumed flavan-3-ol-rich interventions (of apple, cocoa, black tea, green tea, or water [control]) for 1 d each. First morning void samples and 24-h urine samples were collected with diet standardized throughout. For each participant, 1 intervention period was extended (to 2 d) to monitor PVL kinetics after repeat exposure. In the cross-sectional study, 86 healthy participants collected 24-h urine samples, and concurrent weighed food diaries from which flavan-3-ol consumption was estimated using Phenol-Explorer. A panel of 10 urinary PVLs was quantified using liquid chromatography tandem mass spectrometry.
RESULTS
In both studies, 2 urinary PVLs [5-(3'-hydroxyphenyl)-γ-valerolactone-4'-sulfate and putatively identified 5-(4'-hydroxyphenyl)-γ-valerolactone-3'-glucuronide] were the principal compounds excreted (>75%). In the RCT, the sum of these PVLs was significantly higher than the water (control) after each intervention; individually, there was a shift from sulfation toward glucuronidation as the total excretion of PVLs increased across the different interventions. In the extended RCT intervention period, no accumulation of these PVLs was observed after consecutive days of treatment, and after withdrawal of treatment on the third day, there was a return toward negligible PVL excretion. All results were consistent, whether compounds were measured in 24-h urine or first morning void samples. In the observational study, the sum of the principal PVLs correlated dose dependently (R
CONCLUSIONS
Urinary 5-(3'-hydroxyphenyl)-γ-valerolactone-4'-sulfate and putatively identified 5-(4'-hydroxyphenyl)-γ-valerolactone-3'-glucuronide are recommended biomarkers for dietary flavan-3-ol exposure.

Identifiants

DOI: 10.1016/j.tjnut.2023.06.035 PMID: 37394116
pubmed: 37394116
pii: S0022-3166(23)72442-5
doi: 10.1016/j.tjnut.2023.06.035
pii:
doi:

Substances chimiques

flavan-3-ol 35HDD3NRIE
gamma-valerolactone O7056XK37X
Glucuronides 0
Flavonoids 0
Tea 0
Sulfates 0
Biomarkers 0
Catechin 8R1V1STN48

Types de publication

Randomized Controlled Trial Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2193-2204

Informations de copyright

Copyright © 2023 American Society for Nutrition. Published by Elsevier Inc. All rights reserved.

Auteurs

Benjamin H Parmenter (BH)

School of Biomedical Sciences, University of Western Australia, Royal Perth Hospital, Perth, Australia; Nutrition & Health Innovation Research Institute, Edith Cowan University, Perth, Australia.

Sujata Shinde (S)

School of Biomedical Sciences, University of Western Australia, Royal Perth Hospital, Perth, Australia.

Kevin Croft (K)

School of Biomedical Sciences, University of Western Australia, Royal Perth Hospital, Perth, Australia.

Kevin Murray (K)

School of Population and Global Health, University of Western Australia, Perth, Australia.

Catherine P Bondonno (CP)

Nutrition & Health Innovation Research Institute, Edith Cowan University, Perth, Australia; Medical School, University of Western Australia, Perth, Australia.

Angela Genoni (A)

School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.

Claus T Christophersen (CT)

School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.

Keren Bindon (K)

Australian Wine Research Institute, Adelaide, Australia.

Colin Kay (C)

Plants for Human Health Institute, North Carolina State University, Kannapolis, United States.

Pedro Mena (P)

Human Nutrition Unit, Department of Food and Drug, University of Parma, Parma, Italy.

Daniele Del Rio (D)

Human Nutrition Unit, Department of Food and Drug, University of Parma, Parma, Italy.

Jonathan M Hodgson (JM)

Nutrition & Health Innovation Research Institute, Edith Cowan University, Perth, Australia; Medical School, University of Western Australia, Perth, Australia.

Nicola P Bondonno (NP)

Nutrition & Health Innovation Research Institute, Edith Cowan University, Perth, Australia; The Danish Cancer Society Research Centre, Copenhagen, Denmark. Electronic address: n.bondonno@ecu.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Performance of Urinary Phenyl-γ-Valerolactones...
questionsmedicales.fr › Glucides › Oses acides › Acides uroniques › Glucuronates › Glucuronides › Performance of Urinary Phenyl-γ-Valerolactones...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzopyranes › 4H-1-Benzopyran-4-ones › Flavonoïdes › Performance of Urinary Phenyl-γ-Valerolactones...
questionsmedicales.fr › Aliments et boissons › Boissons › Thé › Performance of Urinary Phenyl-γ-Valerolactones...
questionsmedicales.fr › Produits chimiques inorganiques › Sulfates › Performance of Urinary Phenyl-γ-Valerolactones...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Performance of Urinary Phenyl-γ-Valerolactones...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzopyranes › 4H-1-Benzopyran-4-ones › Flavonoïdes › Catéchine › Performance of Urinary Phenyl-γ-Valerolactones...